Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted pipeline therapeutics.
The report provides comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Overview 10
Therapeutics Development 11
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Products under Development by Stage of Development 11
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Products under Development by Therapy Area 12
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Products under Development by Indication 13
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Products under Development by Companies 17
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Products under Development by Universities/Institutes 22
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment 24
Assessment by Monotherapy/Combination Products 24
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 29
AB Science SA 29
Almirall, S.A. 30
Archer Pharmaceuticals, Inc. 31
Asana BioSciences, LLC 32
Celgene Corporation 33
F. Hoffmann-La Roche Ltd. 34
Genosco 35
Gilead Sciences, Inc. 36
GlaxoSmithKline Plc 37
Hutchison MediPharma Limited 38
Levolta Pharmaceuticals, Inc. 39
Merck KGaA 40
Millennium Pharmaceuticals Inc 41
Oscotec Inc. 42
Portola Pharmaceuticals, Inc. 43
Rigel Pharmaceuticals, Inc. 44
Taiho Pharmaceutical Co., Ltd. 45
TopiVert Ltd 46
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles 47
AB-8779 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ASN-002 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
C-13 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CC-509 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
cerdulatinib - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
entospletinib - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
fostamatinib disodium - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
GS-9876 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
GSK-2646264 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
HMPL-523 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
LAS-189386 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
nilvadipine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
PRT-060318 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
PRT-2761 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
R-348 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
RO-9021 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
SKIO-592 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
SKIO-703 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
SKIO-703 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecule to Inhibit SYK for Inflammation - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
TAK-659 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
TAS-5567 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
TOP-1210 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
TOP-1630 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Projects 85
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products 90
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Featured News & Press Releases 91
Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 91
May 16, 2016: TopiVert completes preclinical development with TOP1630 for dry eye disease 92
Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 92
Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 93
Mar 18, 2016: Asana BioSciences, to Provide Update on ASN002, a Novel SYK/JAK Inhibitor, at the 14th International Congress on Targeted Anticancer Therapies 93
Feb 25, 2016: Rigel Initiates Phase II Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia 94
Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 94
Jan 15, 2016: Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia 95
Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 95
Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition 96
Nov 30, 2015: Asana to Present First Clinical Data of ASN002, a Novel SYK/JAK Inhibitor, at American Society of Hematology Annual Meeting 97
Oct 30, 2015: Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers 97
Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 98
May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib 98
May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting 100
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 102
Disclaimer 103
List Of Tables
List of Tables
Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Products under Development by Companies, H2 2016 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Products under Investigation by Universities/Institutes, H2 2016 23
Assessment by Monotherapy/Combination Products, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 28
Pipeline by AB Science SA, H2 2016 29
Pipeline by Almirall, S.A., H2 2016 30
Pipeline by Archer Pharmaceuticals, Inc., H2 2016 31
Pipeline by Asana BioSciences, LLC, H2 2016 32
Pipeline by Celgene Corporation, H2 2016 33
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34
Pipeline by Genosco, H2 2016 35
Pipeline by Gilead Sciences, Inc., H2 2016 36
Pipeline by GlaxoSmithKline Plc, H2 2016 37
Pipeline by Hutchison MediPharma Limited, H2 2016 38
Pipeline by Levolta Pharmaceuticals, Inc., H2 2016 39
Pipeline by Merck KGaA, H2 2016 40
Pipeline by Millennium Pharmaceuticals Inc, H2 2016 41
Pipeline by Oscotec Inc., H2 2016 42
Pipeline by Portola Pharmaceuticals, Inc., H2 2016 43
Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 44
Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 45
Pipeline by TopiVert Ltd, H2 2016 46
Dormant Projects, H2 2016 85
Dormant Projects (Contd..1), H2 2016 86
Dormant Projects (Contd..2), H2 2016 87
Dormant Projects (Contd..3), H2 2016 88
Dormant Projects (Contd..4), H2 2016 89
Discontinued Products, H2 2016 90
Lisst Of Figures
List of Figures
Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Top 10 Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 24
Number of Products by Stage and Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
